We are live on ! Find out more
PFM Health Sciences

PFM Health Sciences Portfolio holdings

AUM $1B Turnover 54.4%
1-Year Est. Return 77.91%
This Fund
S&P 500
This Quarter Est. Return
+4.1%
1 Year Est. Return
+77.91%
3 Year Est. Return
+264.51%
5 Year Est. Return
+347.39%
10 Year Est. Return
+2,853.52%
AUM
$1B
AUM Growth
-$163M
Cap. Flow
-$192M
Cap. Flow %
-19.11%
Top 10 Hldgs %
34.22%
Holding
125
New
27
Increased
26
Reduced
29
Closed
41
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
1 year
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.1 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$24.6M
2
CNMD icon
CONMED
CNMD
+$14.9M
3
ZBH icon
Zimmer Biomet
ZBH
+$14.7M
4
GKOS icon
Glaukos
GKOS
+$13.4M
5
SUPN icon
Supernus
SUPN
+$12.9M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$19M
2
SYK icon
Stryker
SYK
+$17.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$17.7M
4
MTD icon
Mettler-Toledo International
MTD
+$17M
5
HUM icon
Humana
HUM
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 90.51%
2 Miscellaneous 9.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ABVX icon
76
Abivax
ABVX
$7.32B
$2.37M 0.24%
23,906
-19,358
-45% -$2.33M
2025 Q4
3 quarters
GPCR icon
77
Structure Therapeutics
GPCR
$1.33B
$2.08M 0.21%
66,404
-25,146
-27% -$1.18M
2025 Q1
6 quarters
ERAS icon
78
Erasca
ERAS
$5.3B
$1.98M 0.2%
135,068
+980
+0.7% +$17.2K
2026 Q2
1 quarter
TXG icon
79
10x Genomics
TXG
$7.23B
$1.84M 0.18%
+20,376
New +$1.19M
2026 Q3
0 quarters
SVRA icon
80
Savara
SVRA
$984M
$1.78M 0.18%
+345,824
New +$1.91M
2026 Q3
0 quarters
OM icon
81
Outset Medical
OM
$64M
$1.75M 0.17%
582,122
– –
2025 Q1
6 quarters
CGEM icon
82
Cullinan Therapeutics
CGEM
$617M
$1.61M 0.16%
104,715
-87,727
-46% -$1.68M
2025 Q4
3 quarters
SOXX icon
83
iShares Semiconductor ETF
SOXX
$40.8B
$1.39M 0.14%
+7,350
New +$1.31M
2026 Q3
0 quarters
CRBU icon
84
Caribou Biosciences
CRBU
$38.1M
$450K 0.04%
354,687
– –
2021 Q3
20 quarters
ACHC icon
85
Acadia Healthcare
ACHC
$3.6B
– –
-524,934
Closed -$15.5M –
ARGX icon
86
argenx
ARGX
$59.8B
– –
-4,482
Closed -$4.16M –
ARQT icon
87
Arcutis Biotherapeutics
ARQT
$3.43B
– –
-242,069
Closed -$6.35M –
BCRX icon
88
BioCryst Pharmaceuticals
BCRX
$1.92B
– –
-207,357
Closed -$2.07M –
CAPR icon
89
Capricor Therapeutics
CAPR
$483M
– –
-122,221
Closed -$2.94M –
CGON icon
90
CG Oncology
CGON
$7.57B
– –
-128,286
Closed -$9.11M –
CMPS icon
91
Compass Pathways
CMPS
$1.17B
– –
-247,589
Closed -$3.5M –
CNC icon
92
PUT
Centene
CNC
$37B
– –
-88,200
Closed -$5.66M –
COO icon
93
Cooper Companies
COO
$11.8B
– –
-220,890
Closed -$15.8M –
COR icon
94
CALL
Cencora
COR
$68.1B
– –
-28,100
Closed -$7.95M –
COR icon
95
Cencora
COR
$68.1B
– –
-7,385
Closed -$2.09M –
CVS icon
96
CVS Health
CVS
$113B
– –
-137,457
Closed -$14.2M –
CVRX icon
97
CVRx
CVRX
$17.5M
– –
-369,572
Closed -$1.9M –
DNLI icon
98
Denali Therapeutics
DNLI
$2.9B
– –
-100,966
Closed -$2.6M –
GILD icon
99
Gilead Sciences
GILD
$208B
– –
-90,858
Closed -$11.5M –
HIMS icon
100
Hims & Hers Health
HIMS
$4.35B
– –
-49,454
Closed -$1.71M –

Similar funds

PFM Health Sciences's Q3 2026 Portfolio in Review

As of Q3 2026, PFM Health Sciences held 125 positions worth $1B, down 14% from $1.17B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences withdrew a net $192M in Q3 2026, closing 41 positions and reducing 29 holdings. Its most notable exit was Penumbra, an estimated $19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, PFM Health Sciences opened a new position in State Street SPDR S&P 500 ETF Trust worth $24.7M.

  • PFM Health Sciences's largest Q3 2026 buy was State Street SPDR S&P 500 ETF Trust: 32,421 shares worth $24.7M.
  • PFM Health Sciences added most to Supernus in Q3 2026, an estimated $12.9M increase.
  • PFM Health Sciences's biggest Q3 2026 reduction was Jazz Pharmaceuticals, cutting an estimated $17.7M.
  • PFM Health Sciences fully exited Penumbra in Q3 2026, selling an estimated $19M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $1B portfolio in Q3 2026.
  • PFM Health Sciences opened 27 new positions and closed 41 in Q3 2026.
  • PFM Health Sciences's portfolio value fell 14% quarter-over-quarter to $1B.

Based on PFM Health Sciences's 13F filing for Q3 2026, filed 16 Nov 2026.